Functional Neurosurgery · Quick Reference
Antibiotic Prophylaxis & Infection Management in Functional & Epilepsy Neurosurgery
Perioperative prophylaxis and empiric therapy for neuromodulation devices and epilepsy surgery
Surgical-site and device infection is the dominant hardware complication across neuromodulation and a leading source of morbidity in epilepsy surgery. The dosing backbone below is the weight-based regimen shared by the NACC neuromodulation infection guideline and the multisociety (ASHP/IDSA/SIS/SHEA) surgical-prophylaxis guideline. Procedure-specific nuances and the strength of the underlying evidence are noted alongside, followed by a section on empiric antibiotic selection when an infection actually occurs.
Read before you use this reference
This is a consolidated quick reference, not a substitute for your institution's protocol or individualized decision-making. Antimicrobial choice, dosing, and timing should follow local antibiograms, the patient's allergy and colonization status, renal function, and weight, and should be coordinated with anesthesia and pharmacy. The single most impactful, best-supported interventions are weight-based dosing, correct timing relative to incision, and limiting prophylaxis to ≤ 24 hours. Several device- and epilepsy-specific practices below rest on observational data or expert consensus rather than randomized evidence; these are flagged explicitly.
Core agents and dosing
Weight-based IV prophylaxis (NACC Table 7, modified from the ASHP/IDSA/SIS guideline). Doses exceed the MIC at incision and through the case; redosing is rarely needed given the short duration of most of these procedures.
| Agent | Adult IV dose (weight-based) | Timing before incision | Redose | Indication |
|---|---|---|---|---|
| Cefazolin | 2 g (< 120 kg); 3 g (≥ 120 kg) | 30–60 min | ~3–4 h | First-line for all clean neuromodulation and cranial cases. |
| Clindamycin | 900 mg (granular: 600 mg ≤ 80 kg, 900 mg > 80 kg, 1200 mg > 120 kg) | 30–60 min | ~6 h | β-lactam allergy. Not renally cleared. |
| Vancomycin | 15 mg/kg (~1 g ≤ 80 kg, 2 g > 80 kg) | Within 120 min | ~8 h (CrCl > 50) | β-lactam allergy or known MRSA colonization. Not for routine use. |
NACC granular cefazolin tiers: 1 g (≤ 80 kg), 2 g (> 80 kg), 3 g (> 120 kg); the ASHP simplification (2 g / 3 g) is shown above. Vancomycin requires the longer 120-minute lead time because of its slow tissue distribution — a common, consequential timing error.
Why cefazolin first-line — not routine vancomycin or dual coverage
With no β-lactam allergy or known MRSA colonization, cefazolin alone is the evidence-based choice. Substituting vancomycin routinely is associated with higher SSI rates than cefazolin — vancomycin is inferior against MSSA, the commonest pathogen — and broad vancomycin use promotes resistance and a shift toward gram-negative infection. Reserve vancomycin for MRSA carriers and high-risk patients, ideally added to cefazolin rather than replacing it. Routine vancomycin + ceftriaxone (or other dual gram-positive/gram-negative) prophylaxis has not been shown superior to cefazolin alone for clean cases, and cefazolin already carries useful gram-negative activity. Some centers add gram-negative coverage specifically for SCS, given pocket proximity to perineal/skin flora — a reasonable practice pattern, not a guideline mandate.
By procedure
First-line prophylaxis is cefazolin throughout (substitute or add vancomycin for MRSA carriers / high-risk). Infection rates are representative figures from published series, not guideline thresholds.
| Procedure | Prophylaxis | Typical infection rate | Notes & evidence tier |
|---|---|---|---|
| Neuromodulation — spine and intrathecal | |||
| SCS trial (percutaneous) | Cefazolin | low | Externalized leads; do not extend antibiotics through the trial beyond the periprocedural dose. NACC guideline. |
| SCS / DRG permanent implant | Cefazolin (vanco for MRSA) | ~3–4% | Pocket and lead. Covered directly by the NACC device guideline. Consensus + observational. |
| Intrathecal pump implant | Cefazolin | ~2–4% | High-consequence (meningitis, catheter-tract infection). NACC guideline. |
| Neuromodulation — cranial and generator | |||
| DBS lead implant | Cefazolin; many add/substitute vancomycin for the lead stage | ~3–5% (older series higher) | Cranial entry plus chest IPG pocket. No long-standing society guideline; a 2025 modified-Delphi consensus is the first DBS-specific document. Consensus / practice pattern. |
| IPG / battery replacement | Cefazolin | lower than implant; rises with reoperation | Pocket-only, shorter case. Cefazolin alone is common practice. Practice pattern. |
| RNS (cranially implanted neurostimulator) | Cefazolin | ~3.7% per procedure | Skull-seated device; risk of bone-flap osteomyelitis. Infection risk is driven by reoperations. Observational. |
| VNS (generator + lead) | Cefazolin | low single digits | Neck incision plus chest pocket; deep infection usually requires explantation. Practice pattern. |
| Epilepsy surgery | |||
| SEEG (depth electrodes) | Per-protocol cefazolin | ~0.3% | Low infection rate; evidence for any prophylaxis beyond a single periprocedural dose is weak. Infection is managed by electrode removal + IV antibiotics. Weak / per usual surgical protocol. |
| Subdural grids / strips | Cefazolin; many continue while hardware is externalized | ~1.8% (higher than SEEG) | Externalized leads during prolonged monitoring raise risk; continuing antibiotics through the monitoring period is common but not supported by strong evidence. Practice pattern / contested. |
| Resective surgery / craniotomy | Cefazolin, single preoperative dose | clean-cranial baseline | Within 60 min of incision; redose for long cases or major blood loss; stop within 24 h. Multisociety surgical-prophylaxis guideline. |
The perioperative bundle (beyond the antibiotic)
The NACC infection guideline frames prophylaxis as one element of a bundle; the antibiotic alone is not enough:
- Weight-based dosing — underdosing (e.g., 1 g cefazolin in a heavy patient) is a documented driver of higher SSI rates.
- Timing — cephalosporins 30–60 min before incision; vancomycin within 120 min.
- Skin antisepsis — chlorhexidine-gluconate / alcohol preparation is preferred.
- Hair removal — only if necessary, with electric clippers immediately before surgery; never a razor.
- MRSA — screen S. aureus carriers and decolonize (nasal mupirocin twice daily + chlorhexidine baths); reserve vancomycin for carriers and high-risk patients to limit resistance.
- Duration — discontinue within 24 hours; NACC specifically advises against continuing antibiotics beyond 24 h for neuromodulation trials and implants.
Intraoperative adjuncts
Beyond systemic prophylaxis, several intraoperative measures are debated. The evidence quality varies widely; only irrigation with saline and the antimicrobial envelope (in selected patients) carry guideline support.
| Adjunct | What the evidence shows | Bottom line |
|---|---|---|
| Saline irrigation (bulb syringe, low pressure) | Standard practice; high-pressure pulsed lavage can disrupt tissue planes and drive bacteria deeper. | NACC-recommended before closure. Use low-pressure saline. |
| Antibiotic-added irrigation (e.g., bacitracin) | Not shown superior to saline alone; raises resistance concerns, and some agents impair wound healing. | Not recommended over plain saline. |
| Dilute povidone-iodine irrigation | Some supportive data in spine/orthopedic surgery; CDC offers a weak "may consider" for clean wounds. | Optional; weaker, mixed evidence. Reasonable adjunct. |
| Intrawound vancomycin powder | Early observational/registry data favorable (SSI ~4% → ~1.3% in pooled cohorts); recent RCT-level meta-analyses (2024, 7 RCTs) show no significant reduction in superficial or deep SSI. | Low-cost, widely used; an institutional choice, not guideline-mandated. Evidence has weakened with better trials. |
| Antimicrobial envelope (TYRX; minocycline + rifampin) | WRAP-IT RCT in cardiac devices (n ≈ 7000): 40% fewer major and 61% fewer pocket infections. Neuromodulation-specific data are limited/extrapolated. | NACC: consider around IPG pockets in high-risk patients (e.g., reoperation, prior infection). Not routine for all. |
MRSA / S. aureus screening and decolonization
Roughly a quarter to a third of patients carry S. aureus in the nares, carriers have a two- to nine-fold higher SSI risk, and most healthcare-associated S. aureus SSIs are endogenous — which is why preoperative screening and decolonization is one of the better-supported bundle elements. Decolonization protocol: intranasal mupirocin twice daily plus daily chlorhexidine-gluconate baths, typically for ~5 days before surgery. In a landmark trial, decolonization reduced SSI from 4.4% to 0.9% in carriers, and a meta-analysis of nine RCTs confirmed fewer S. aureus infections in treated carriers. The NACC recommends screening S. aureus carriers and decolonizing positives, and reserving vancomycin coverage for MRSA carriers and high-risk patients to limit resistance. Targeted (screen-and-treat) and universal (decolonize all without screening) strategies are both used; targeted is more common for elective device implantation, while universal protocols suit settings with high MRSA prevalence or where screening turnaround is impractical.
How to read the evidence tiers
Published guideline: the core dosing, timing, MRSA, and duration recommendations (NACC neuromodulation infection guideline; multisociety surgical-prophylaxis guideline). Consensus / practice pattern: DBS (emerging 2025 Delphi consensus), RNS, VNS, and externalized-electrode management — cefazolin is extrapolated from the device/cranial backbone in the absence of dedicated randomized data. Contested / weak: intrawound vancomycin powder and prolonged antibiotics during subdural-grid monitoring. Where a practice is not guideline-grade, the procedure table says so.
Empiric therapy when infection occurs
Once an SSI or device infection is suspected, obtain cultures and begin treatment promptly; refine by speciation and sensitivities. The NACC supplies the management framework (recognition, source control, infectious-disease consultation, re-implantation); the specific empiric drugs below follow standard infectious-disease practice and should track local antibiograms.
Likely organisms by setting:
| Setting | Predominant organisms | Also consider |
|---|---|---|
| Device / hardware SSI (any site) | S. aureus (MSSA and MRSA); coagulase-negative staphylococci (S. epidermidis) | Gram-negative bacilli (E. coli, Pseudomonas), less common |
| Cranial hardware (DBS, RNS), indolent course | Cutibacterium (Propionibacterium) acnes; coagulase-negative staphylococci | S. aureus |
| Deep neuraxial / epidural abscess | S. aureus (most common) | Enterococcus, gram-negative bacilli, anaerobes; mycobacteria/fungi rare |
| CSF / intrathecal pump (meningitis) | Coagulase-negative staphylococci; S. aureus | Gram-negative bacilli |
Empiric IV regimens pending culture:
| Clinical picture | Empiric regimen (pending cultures) | Notes |
|---|---|---|
| Superficial pocket cellulitis, remote from the neuraxis | Oral anti-staphylococcal agent (cephalexin; doxycycline or TMP-SMX if MRSA risk) + close follow-up | Can track along hardware; low threshold to image and escalate. Selected cases are salvageable without explant. |
| Deep device / hardware infection | Vancomycin + an antipseudomonal β-lactam (cefepime or piperacillin-tazobactam) | Pair with source control — deep hardware infection usually requires explant. Biofilm limits salvage; involve ID. |
| Suspected CNS involvement / meningitis / epidural abscess | Vancomycin + cefepime (or ceftazidime / meropenem) at CNS-penetrating, meningitic doses | Surgical emergency once a neurologic deficit appears; obtain neuraxial imaging; ID consult and meningitic dosing. |
Management principles
- Cultures first when stable — obtain specimens before antibiotics if the patient is stable, but do not delay empiric therapy in a deteriorating or septic patient; refine on sensitivities.
- Source control is decisive — deep or hardware-associated infection usually requires explantation (conservative DBS salvage succeeds in < 40%, owing to biofilm). Superficial infection may be managed with antibiotics and wound care.
- Coverage logic — vancomycin covers MRSA, MSSA, and coagulase-negative staphylococci; add gram-negative / antipseudomonal cover empirically; cephalosporins do not cover enterococci. When Cutibacterium is suspected (cranial hardware), hold cultures 10–14 days.
- Duration — narrow to culture; deep, retained-hardware, or osteomyelitic infection often needs ~4–6 weeks of IV therapy — set with infectious disease.
- Monitoring — CRP kinetics (failure to normalize or a secondary rise) is the most useful laboratory marker; ESR responds more slowly.
- Infectious-disease consultation — recommended for the definitive regimen, treatment duration, and re-implantation timing.
References
- Deer TR, Provenzano DA, Hanes M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) recommendations for infection prevention and management. Neuromodulation. 2017;20(1):31–50. PubMed
- Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery (ASHP, IDSA, SIS, SHEA). Am J Health-Syst Pharm. 2013;70(3):195–283 / Surg Infect. 2013;14(1):73–156. PubMed
- Deer TR, Russo MA, Grider JS, et al. The Neurostimulation Appropriateness Consensus Committee (NACC): recommendations for the mitigation of complications of neurostimulation. Neuromodulation. 2024;27(6):977–1007. PubMed
- Bjerknes S, Skogseid IM, Saehle T, et al. Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period. PMC
- Weber PB, Kapur R, Gwinn RP, et al. Infection and erosion rates in trials of a cranially implanted neurostimulator do not increase with subsequent neurostimulator placements. Stereotact Funct Neurosurg. 2017;95(5):325–329. PubMed
- Yang JC, et al. Seizure outcomes and complications of SEEG versus subdural electrodes for invasive monitoring: a meta-analysis. PMC
- Intraoperative vancomycin for preventing infection after open spine surgery: a systematic review and meta-analysis of randomized controlled trials (7 RCTs, 2235 patients; no significant SSI reduction). PubMed
- Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial envelope to prevent cardiac implantable device infection (WRAP-IT). N Engl J Med. 2019;380(20):1895–1905; long-term follow-up Heart Rhythm. 2020. PubMed
- Vancomycin antibiotic prophylaxis compared to cefazolin increases risk of surgical site infection following spine surgery. PubMed
Infection-rate figures are representative values drawn from the cited series and reviews; they describe published experience and are not guideline-defined thresholds. Confirm agent, dose, and timing against your institutional protocol and current guidance.